Overview
Neuraltus Pharmaceuticals is developing NP001, a novel immunomodulatory therapy targeting neuroinflammation in ALS patients by reprogramming inflammatory macrophages and microglia.
More in Neuropharmaceuticals
Latest industry news
Tianjin University Unveils a 3-Gram Non-Invasive BCI That Disappears Into Your Hair
2026-10-04 · Research
Neuralink Pretrained on 50,000 Hours of Unlabeled Brain Data — and the Implications Are Enormous
2026-10-03 · Research
BlueWind Medical Wins Category I CPT Code for Subfascial Tibial Neuromodulation
2026-10-02 · Policy
Neurable One Brings Brain-Computer Interface Technology to Consumer Wireless Headphones
2026-10-01 · Product
Company details
Category
💊 Neuropharmaceuticals
Location
Palo Alto, CA, USA
Funding
Series B · $30M
Website
www.neuraltus.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →